In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

"We were delighted to discover not only important details about the mechanisms of HBV gene regulation, but also a promising ...

Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, ...

Precision BioSciences (NASDAQ:DTIL) added ~6% in the premarket on Wednesday after the gene therapy developer announced ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

Precision BioSciences (DTIL) announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ...

Savage resident Edwin Tan spent his summer carrying a message across the triathlon finish line. Tan, 29, lives with chronic hepatitis B. He said there isn’t a lot of public ...

Research conducted by a local hospital has found that hepatitis B patients with a simple fatty liver have a lower mortality ...